chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Admission HPI: Right-sided chest pain began 2 days prior to admission (3/19) after getting out of car, without identifiable trigger. Pain was sharp, pleuritic, and worst with movement; didn't feel it when still. Pain not responsive to ibuprofen or heating packs. Reported 30-60 seconds of self-resolving heart racing during ocular migraine which has been his baseline for years. Not associated with SOB (at rest or with exercise), palpitations, presyncope, or syncope. No viral URI symptoms, N/V, or rash. He did receive his 2nd Moderna COVID vaccine about 1 week PTA, followed by 36hrs of fevers, chills, and body aches. Given persistence of pain, Patient asked his parents to present to urgent care.   In UC, he was noted to tachycardic with CXR with bibasilar atelectasis and b/l effusions, per report. Given continued tachycardia, decision was made to transfer to ED to r/o PE.      In ED, tachycardic to 104-116 and tachypneic 22-26. Had one episode of tachycardia to 182 iso ocular migraine. Endorsed chest pain but points to R middle abdomen when asked where worst. Exam was unremarkable. He received 1 dose of morphine which reduced pain from 10/10 to 0/10. Labs notable for leukocytosis (14.61), thrombocytopenia (422), elevated d-dimer (1.56), and elevated CRP (5.6). Otherwise normal chem and coags. COVID/RVP negative. CXR unremarkable. CTPA showed scattered PEs in b/l lower lobes with small pulmonary infarct in RML. No evidence of right heart strain. Heme was consulted who recommended starting him on lovenox and sending lupus anti-coagulant. Cardiology was consulted who recommended EKG, BNP, and troponin, all of which were normal and reassuring against right heart strain. ECHO was therefore deferred to the AM. The decision was made to admit.   Upon arrival to the floor, Patient was tachycardic 114 and tachypneic to 22, otherwise stable vitals. He denied any pain since morphine. Denied any unexpected weight loss; reports that car ride was short. Mom reports that Patient has been less active d/t cold weather and baseball being on hold. Denies family or personal history of clots. Last seizure ~13 years ago.  Hospital Course: (3/21 - 3/22)  Patient was admitted to the hematology service. He was therapeutically anticoagulated with LMWH injections and his anti-Xa level prior to discharge was 0.92. (goal 0.5-1.0) Lower extremity ultrasound with Doppler showed patent veins and no evidence of DVT and upper extremity ultrasound showed no evidence of DVT, though there was potential evidence of collateralization seen in mid and distal third of right subclavian vein and left internal jugular vein. Since this was an unprovoked PE, a full thrombophilia workup was sent and will be followed up by the outpatient hematology clinic. Cardiology consulted regarding possibility of right heart strain and the tachycardia during migraine episodes. Echocardiogram performed on 3/22 was technically limited but showed no gross abnormalities. The cardiology team requested a repeat echo scheduled outpatient for 1-2 months after discharge.
Pt woke up during the night w/inc temp of 103 A & hives on legs, face, & arms; pt recvd APAP & temp dec to 102 Ax; hives on face gone now; 9AM still has hives on legs & some on arms; MD also prescribed DPH;
rising area; rising area that is hot to touch; Red / arm has red; This case was reported by a pharmacist via call center representative and described the occurrence of injection site swelling in a 67-year-old female patient who received Herpes zoster (Shingrix) (batch number 52R7X, expiry date 10th October 2021) for prophylaxis.   Previously administered products included Shingrix (1st dose received on unknown date and no reaction to the first dose.).   On 5th November 2019, the patient received the 2nd dose of Shingrix (intramuscular) .5 ml. On 5th November 2019, less than a day after receiving Shingrix, the patient experienced injection site swelling, injection site warmth and injection site erythema. On an unknown date, the outcome of the injection site swelling, injection site warmth and injection site erythema were not recovered/not resolved.   It was unknown if the reporter considered the injection site swelling, injection site warmth and injection site erythema to be related to Shingrix.  Additional case details were reported as follows: The patient received vaccine in right arm. The patient's arm had red, rising area that was hot to touch (at the injection site). It started in the afternoon of the injection and was about the same. The patient would also having a heart catheter a day after reporting, noted in report in case significant for reporting. The reporter consent to follow up.
I've been vaginally bleeding for 2 weeks. Bleeding began hours after the vaccination and has not stopped since.
started running temp & fussy about 130PM 13JUL; 5AM 14NOV pt stopped breathing, eyes rolled back, felt very hot; mom gave pt APAP but did not help fever; mom did CPR; pt had a sz; pt had febrile sz;
This spontaneous report as received from a nurse refers to multiple unspecified patients of unknown age and gender. There was no information about patients' concomitant medications and pertinent medical history reported. On an unknown dates, multiple unspecified patients were vaccinated with improperly stored doses of VARIVAX lot # L017142, expiry date 13-MAY-2017 (routes and sites of administration, dose were not reported). No adverse effects were reported. Follow-up information was received on 07-DEC-2015, that all telephone attempts to obtain follow-up information have been unsuccessful. Follow-up information has been received on 08-DEC-2015 from the reporting nurse. She reported that she would have to research the request made for patient identifiers, lot number and expiration date and dates of vaccination. Follow up information has been received from the nurse on 14-DEC-2015. This case concerns a 15 year old patient. On 15-SEP-2015, the patient was vaccinated with VARIVAX. This is one of several reports received from the same reporter. Additional information has been requested.
heartrate went up to 153 BPM; This spontaneous case was reported by a consumer and describes the occurrence of TACHYCARDIA (heartrate went up to 153 BPM) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 27-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-May-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced TACHYCARDIA (heartrate went up to 153 BPM). On 27-May-2021, TACHYCARDIA (heartrate went up to 153 BPM) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Heart rate: 153 (High) 153 BPM.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment information was unknown.  Patient stated that after she read a brochure about what an allergic reaction to the vaccine could look like, she mentions that she had a similar reaction to MRI scan dye at hospital several years ago.   Most recent FOLLOW-UP information incorporated above includes: On 09-Jun-2021: TCR : Patient added she is feeling well.
Constant left arm (injection arm) shoulder collar bone shoulder blade pain that increases with motion, especially raising the left arm above the head.
Major pain in right big toe joint; Gout; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 02Apr2021 at 11:15 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. The patient's medical history reported as not applicable. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 11Mar2021 at 10:00 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. On 03Apr2021 at 01:00, also reported as approximately 12 hours after the second shot, the patient experienced major pain in right big toe joint that was later diagnosed to be gout. The patient had never had gout before that. The events resulted in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of major pain in right big toe joint and gout and included treatment with colchicine (MANUFACTURER UNKNOWN). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcomes of the events major pain in right big toe joint and gout was resolving at the time of report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
This case was reported by a consumer and described the occurrence of injection site swelling in a patient who received Influenza vaccine. On an unknown date, the patient received Influenza vaccine at an unknown dose. On an unknown date, unknown after receiving Influenza vaccine, the patient experienced injection site swelling, injection site warmth, injection site erythema and injection site pain. On an unknown date, the outcome of the injection site swelling, injection site warmth, injection site erythema and injection site pain were recovered/resolved. It was unknown if the reporter considered the injection site swelling, injection site warmth, injection site erythema and injection site pain to be related to Influenza vaccine. This case is linked to case US2015057042 as same patient.
Information has been received from a medical assistant regarding two patients who were vaccinated with a dose of PNEUMOVAX 23. It was reported that two patients developed cellulitis after receiving a dose of PNEUMOVAV 23. One patient received PNEUMOVAX 23 on 03-AUG-2012 and the other patient received PNEUMOVAX 23 on 06-AUG-2012 (MARRS# 1210USA003251). It was reported both patients were vaccinated with a dose PNEUMOVAX 23 (Lot number 672041/1477AA; expiration date 14-MAY-2013) 5 ml. Conflicting information, expiration date 14-MAY-2012 also reported. No further information was provided.
Second dose lot  # 028L20A, in left arm.  My left arm swelled up turned pinkish went to ER, had blood clot in left subclavian vein. Clot removed sent home on Eliquis, went to post op sent back to ER with subclavian blood clot in left arm, clot removed, rib removed, sent home on Eliquis, at post op ultrasound sent to ER for third blood subclavian blood clot in left arm. Now on twice a day injections of Lovenox.
A few weeks after the first shot, I started waking up in the mornings and couldn't go back to sleep. After the second shot, things got worse, and I started realize that it was sleep apnea. I went to the doctor and I am currently being evaluated for central sleep apnea. My breathing stops, and then I wake when I need to grasp for air. I am healthy guy that works out and in good shape. This came out of nowhere and I am worried it has to do with taking the Moderna vaccine.
5 days after initial vaccine site became itchy and then a large red oval appeared; swollen, hot and itchy; small rash with scabs appeared a few days later.
Patient received 2nd COVID immunization.  Approximately 10 minutes after receiving vaccine she stated she didn't feel well.  She the passed out and started shaking.  We laid her down on her left side and she came to in about 20 seconds.  EMS was contacted.  Ambulance stated her blood pressure was 100/60.  She went to hospital with ambulance following her.
experienced heart area/chest pain, sometime dull sometimes sharp pain; experienced heart area/chest pain, sometime dull sometimes sharp pain and discomfort; nausea; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 53 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 17Mar2021 11:00 (Lot number: EN6208) at the age of 53 years as dose 1, single and administered in arm left, administration date 12Apr2021 11:00 (Lot number: EW0150) as dose 2, single for covid-19 immunisation. Relevant medical history included: "Asthma" (unspecified if ongoing); "Allergies: sulfite" (unspecified if ongoing); "Allergies: penicillin" (unspecified if ongoing); "Known allergies: Aspirin" (unspecified if ongoing). Concomitant medication(s) included: PROAIR [SALBUTAMOL SULFATE]; PULMICORT. The following information was reported: CHEST PAIN (non-serious) with onset 2021, outcome "recovered with sequelae", described as "experienced heart area/chest pain, sometime dull sometimes sharp pain"; CHEST DISCOMFORT (non-serious) with onset 2021, outcome "recovered with sequelae", described as "experienced heart area/chest pain, sometime dull sometimes sharp pain and discomfort"; NAUSEA (non-serious) with onset 2021, outcome "recovered with sequelae", described as "nausea". Therapeutic measures were not taken as a result of chest pain, chest discomfort, nausea.  Additional information: The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient received ProAir Inhaler sometimes, Pulmicort 180mcg often within 2 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19.  Follow-up attempts are completed. No further information is expected.
Indurated erythematous whelts at site of DTaP/IPV spread over next 24-48 hrs to involve majority of body. Treated with Benadryl/Atarax.
Rush throughout body, then passed out.  Immediate recovery.  Paramedics @ side.   Refused transport to hospital.
Getting COVID After the Vaccine; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Getting COVID After the Vaccine) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   In January 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In February 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (Getting COVID After the Vaccine). At the time of the report, COVID-19 (Getting COVID After the Vaccine) outcome was unknown.            No concomitant medications  were reported.  NO Treatment medications were reported.
Fever after 2nd dose; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever after 2nd dose) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032m20a) for COVID-19 vaccination.     No Medical History information was reported.   On 15-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Mar-2021, the patient experienced PYREXIA (Fever after 2nd dose). The patient was treated with IBUPROFEN for Fever, at an unspecified dose and frequency. At the time of the report, PYREXIA (Fever after 2nd dose) had not resolved. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 99.6 (Inconclusive) slight fever of 99.6.         Action taken with mRNA-1273 in response to the events was not Applicable.  Concomitant product use was not provided by the reporter.
Extreme Vomiting (5 times); extreme soreness of arm; stomach pain; fatigue; Insomnia; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 25Apr2021 at 14:30 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic pancreatitis, diabetes, insomnia and blood pressure high. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included paracetamol (TYLENOL), ibuprofen (MANUFACTURER UNKNOWN) and naproxen (MANUFACTURER UNKNOWN); all were taken for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously took morphine (MANUFACTURER UNKNOWN) and experienced drug allergy. On 25Apr2021 at 20:00, the patient experienced extreme vomiting (5 times), extreme soreness of arm, stomach pain, fatigue and insomnia. The events did not result in doctor or other healthcare professional office/clinic visits, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events extreme vomiting (5 times), extreme soreness of arm, stomach pain, fatigue and insomnia was not recovered at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
sharp cry, would not sleep for 12 hrs; parent treated w/APAP-t99.7
02/04/08 received vaccines @ 0930A. At 0730P started crying, high pitched. Child couldn't be consoled. Around 0830P child had staring event followed by mild jerking, lasting approx 1 minute. Called Dr. on 2/5/08, not seen was told to monitor child.
Patient was given adult dose (1ml) of Hep A instead of pediatric dose (0.5ml). Patient did not have any reaction to the larger dose and is doing fine.
This spontaneous report as received from a medical assistant refers a patient of unknown demographics. On an unknown date, the patient was vaccinated with a dose of improperly stored GARDASIL (Lot number, expiry date, route and dose were not reported). The medical assistant reported that the vaccine was exposed to temperature of 26 F for a total of 135 hours. No adverse effects reported. Follow-up received. Medical assistant stated that other 104 children received GARDASIL. Follow up information has been received from the medical assistant regarding a 13 years old, female patient with no pertinent medical history reported. On 15-NOV-2012 the patient was vaccinated with GARDASIL (lot number and expiration date not reported) (intramuscular on the right arm, dose not reported). Concomitant medications included Hepatitis A vaccine (manufacturer unknown) (lot number and expiration date not reported) (intramuscular on the left arm, dose not reported). It was reported that the patient did not seek medical attention. This is one of the several reports from the same source. Additional information is not expected.
Severe nausea Severe muscle cramping Numbness in upper legs Severe back pain Throwing up Severe exhaustion
Flu like symptoms ache all over slight fever. All subsided after 12 hours then 12 hours later fever spiked and aches returned with vengence. On and off for 4 days now.
Vertigo, dizziness, light headed, nausea - no treatment, follow up with ENT - diagnosed with Vestibular Neuronitis Doctor said it could be weeks/months for inflammation to go down.
24 year old female patient 4+ months pregnant. Patient received TD, MMR, Varicella.
Around 8:30 pm on 02/20/2012, Pt's mom states the pt c/o her leg being very sore and not wanting to bear weight on the R leg. Mom states she give the pt Tylenol and placed warm compresses on the pt's R thigh, which mom described a being red and swollen and painful to the touch. On 02/22/2012 at 3:15PM, Pt was brought in to the Health Dept. It was noted that pt had a large red raised area to upper R thigh, measuring approx 3in x 3in. The area was warm to the touch and painful to the touch. Pt was able to bearing weight on the leg and walked fine on that leg. This was observed by 2 RN's. Mom states that the pt has not had any fever or unconsolible crying since being vaccinated. Instructed mom to take pt to see her PMD for further evaluation on the R thigh.
Patient described feeling nauseated first BP 91/59, 120/66, Temp: 98.6 Pulse 61 o2 99%
3 days after nasal administration of vaccine, patient developed persistent fever to 103.7, myalgias, nasal congestion, anorexia, fatigue.  So far, this has lasted for 4 days.
Breakthrough case admission after 2 vaccines Pfizer 4/16/21 lot# EW0150;  Pfizer 5/7/21 lot# Ew0172
Within 24 hours - fever, body aches, nausea, fatigue, injection site pain and redness, headache - Form being completed 3 days after injection + Sx persist. Chills and sweats, Deltoid and axillary pain.
developed tinnitus after the booster shot.; This spontaneous case was reported by a consumer and describes the occurrence of TINNITUS (developed tinnitus after the booster shot.) in a 60-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Benign prostatic hyperplasia. Concurrent medical conditions included Asthma.   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced TINNITUS (developed tinnitus after the booster shot.). At the time of the report, TINNITUS (developed tinnitus after the booster shot.) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Antibody test: 57 index Antibody test read 57 index. No concomitant medications were reported.  It was reported that the vaccination facility had stated that since the patient had asthma, they considered the patient as immunocompromised and suggested the patient had to get third full dose. However, the patient had stated that he did not consider himself as immunocompromised and was also never officially diagnosed as so. The patient stated that he had refused the full third dose and decided to get a booster half shot.  No treatment medications were reported.
Small dot of redness and irritation on left thigh at site of injection.  At 05:00 PM today, large red rash noted around site (Approximately 4" by 4").  Child reporting mild pain and irritation at site.  Pt assessed by triage RN, myself, and MD.  MD advised Tylenol for pain and warm compress to the site to help alleviate symtoms.  Call if change in status.
Swelling L thigh noted the night of vaccination.  Non tender, erythematous swelling.  Afebrile; gait N1.
A report has been received from a Health Professional concerning a patient, male subject, who had been receiving FLUMIST QUADRIVALENT (intranasal). FLUMIST QUADRIVALENT (intranasal) started on an unknown date. It was reported that several patients received only a half dose of FLUMIST QUADRIVALENT. The outcome of the event of multiple patients received a half dose of FLUMIST QUADRIVALENT is unknown. The report was considered to be non-serious.